Loading company…
Oncopeptides AB is a Stockholm pharmaceutical company developing anti-cancer drugs, including Melflufen.
Founded in 2000 and based in Stockholm, Sweden, Oncopeptides AB develops anti-cancer drugs for cancer patients, including Melflufen, a treatment for hematological cancers. In November 2021 the company raised EUR 30 million in venture debt funding from the European Investment Bank.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in